Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 50, Issue 9, Pages 101S-112SPublisher
WILEY-BLACKWELL
DOI: 10.1177/0091270010376966
Keywords
Granulocyte-colony stimulating factor; neutrophils; granulopoiesis; target-mediated drug disposition; mechanistic models
Categories
Funding
- Novartis Pharma AG
- Laboratory for Protein Therapeutics University at Buffalo
- American Conference on Pharmacometrics
Ask authors/readers for more resources
Filgrastim is a recombinant human granulocyte colony stimulating factor (G-CSF) that stimulates production of neutrophils. The objective of this analysis was to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model to account for an increase in G-CSF clearance on multiple dosing because of an increase of the G-CSF receptor-mediated endocytosis. Data from 4 randomized studies involving healthy volunteers were used for analysis. Subjects received filgrastim (Neupogen) via subcutaneous (SC) and intravenous (IV) routes. Filgrastim was administered SC daily for 1 week at 2.5, 5, and 10 mu g/kg doses and as single IV infusions (5 mu g/kg over 0.5 hours) and SC (1 mu g/kg) doses. PK data comprised serum concentration-time measurements and the blood absolute neutrophil count (ANC) was used for PD evaluations. Population nonlinear mixed-effect modeling was done using NONMEM VI (Version 6.1.0, Icon Development Solutions, Ellicott City, Maryland). The model depicted the decaying trend in C-max values with repeated doses and an increase in ANC(max) values consistently with an increase in the G-CSF receptor pool. Simulated time courses of the total clearance exhibited an increasing pattern. The increase in filgrastim clearance on multiple dosing was attributed to the increased neutrophil count in the bone marrow and blood paralleled by an increase in the total G-CSF receptor density.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available